The influence of GLP-1 on glucose-stimulated insulin secretion: Effects on β-cell sensitivity in type 2 and nondiabetic subjects

• Published in: Diabetes (New York, N.Y.) Vol. 52; no. 2; pp. 380 - 386
• Main Authors: KJEMS, Lise L, HOLST, Jens J, VØLUND, Aage, MADSBAD, Sten
• Format: Journal Article
• Language: English
• Published: Alexandria, VA American Diabetes Association 01.02.2003
• Subjects: Area Under Curve; Biological and medical sciences; Blood Glucose - drug effects; Blood Glucose - metabolism; C-Peptide - blood; Care and treatment; Diabetes Mellitus, Type 2 - blood; Diabetes Mellitus, Type 2 - physiopathology; Diabetes. Impaired glucose tolerance; Endocrine pancreas. Apud cells (diseases); Endocrinopathies; Etiopathogenesis. Screening. Investigations. Target tissue resistance; Female; Glucagon; Glucagon - administration & dosage; Glucagon - pharmacology; Glucagon - physiology; Glucagon-Like Peptide 1; Glucose Clamp Technique; Humans; Infusions, Intravenous; Insulin - metabolism; Insulin Secretion; Islets of Langerhans - drug effects; Islets of Langerhans - metabolism; Kinetics; Male; Medical sciences; Peptide Fragments - administration & dosage; Peptide Fragments - pharmacology; Peptide Fragments - physiology; Physiological aspects; Protein Precursors - administration & dosage; Protein Precursors - pharmacology; Protein Precursors - physiology; Reference Values; Type 2 diabetes; Denmark; Endocrinopathy; Human; Gastrointestinal hormone; Sensitivity resistance; Diabetes mellitus; β Cell; Glucose; Insulin; Endocrine pancreas; Glucagon like peptide 1

The intestinally derived hormone glucagon-like peptide 1 (GLP-1) (7-36 amide) has potent effects on glucose-mediated insulin secretion, insulin gene expression, and beta-cell growth and differentiation. It is, therefore, considered a potential therapeutic agent for the treatment of type 2 diabetes....